White & Case has advised J.P. Morgan Securities LLC, SVB Leerink LLC, BofA Securities, Inc., Evercore Group L.L.C. and RBC Capital Markets, LLC as representatives of...
Intra-Cellular Therapies’ $460 Million Shares Offering
TPG’s $1 Billion Initial Public Offering
Davis Polk & Wardwell and Shearman & Sterling advised TPG, while Ropes & Gray acted as counsel to the underwriters in the IPO. TPG, a leading...
CinCor Pharma’s $193.6 Million IPO
Wilmer Cutler Pickering Hale and Dorr advised the underwriters on the deal. CinCor Pharma, Inc. (“CinCor”) (Nasdaq: CINC), a clinical-stage biopharmaceutical company focused on developing its...
ProKidney’s Combination With Social Capital Suvretta Holdings Corp. III
Wachtell, Lipton, Rosen & Katz acted as legal advisor to SCS. Davis Polk & Wardwell and Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C, Matheson, Akin...
Amylyx Pharmaceuticals’ $190 Million IPO
Wilmer Cutler Pickering Hale and Dorr advised the underwriters on the deal while Goodwin Procter represented Amylyx Pharmaceuticals. Amylyx Pharmaceuticals, Inc. (“Amylyx”), a clinical-stage pharmaceutical company...
Stryker’s Acquisition of Vocera Communications
Skadden, Arps, Slate, Meagher & Flom advised Stryker on the deal, while Fenwick & West represented Vocera Communications. Debevoise & Plimpton advised Evercore LLC as financial...
DuPont’s $5.2 Billion Acquisition of Rogers Corporation
Skadden, Arps, Slate, Meagher & Flom advised DuPont on the deal while Covington & Burling represented Rogers Corporation. Fried Frank acted as counsel to Evercore as...
Learn CW Investment’s $230 Million Initial Public Offering
Shearman & Sterling advised Evercore ISI as the sole book-running manager on the initial public offering. Learn CW Investment, a SPAC, executed its 23 million units...
Thorne HealthTech’s $70 Million Initial Public Offering
Wilson Sonsini Goodrich & Rosati represented Thorne HealthTech, while Latham & Watkins represented the underwriters in the offering. Thorne HealthTech, a leader in developing innovative solutions...
Viridian Therapeutics’ $97.7 Million Shares Offering
Wilmer Cutler Pickering Hale and Dorr advised the underwriters on the deal. Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company advancing new treatments for patients suffering...
AMCI Acquisition Corp. II’s $150 Million Initial Public Offering
White & Case advised AMCI, while Cravath, Swaine & Moore advised the underwriters in the transaction. AMCI Acquisition Corp. II executed the $150 million initial public offering...
Eliem Therapeutics’ $80 Million Initial Public Offering
Latham & Watkins represented the underwriters in the offering. Eliem Therapeutics, Inc., a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders to...